Holland exits Mauritskliniek in sale to PE-backed Corius

The deal allows Corius, which operates in Germany and Switzerland, to enter the Dutch market. 

Mauritskliniek provides healthcare services in dermatology, varicose veins, proctology, skin therapy and medical-cosmetic care. The company had revenue of around EUR 12.5m, according to filed accounts. 

Holland Capital first signalled its intention to sell Mauritskliniek to Corius in July with the deal now approved by Dutch competition authorities. 

The GP's plan to sell Mauritskliniek to Bergman Clinics, a local chain of general outpatient clinics, was blocked at the end of 2021 after regulators decided it would inadequately strengthen the group's relationship with health insurers, as reported.

Holland acquired the clinic chain in March 2017; at the time the sponsor was deploying capital from its third buyout fund, Holland Venture Entrepreneurs Fund III, which closed in December 2016 at EUR 55m.

Earlier this year, Corius' sponsor Ufenau raised a EUR 536m continuation vehicle for the dermatology platform and equine veterinary company Altano, as reported. 

Ufenau saw more room for growth and M&A in both assets, as reported.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• DACH
• Healthcare
• Exits
• Expansion
• GPs
• Ufenau Capital Partners
• Holland Capital Management B.V.
• Netherlands